A US court approved a settlement worth up to $7.25 billion linked to Roundup, the world’s best-selling herbicide, in a case tied to allegations that the product causes cancer. The agreement was approved on Friday by a judge in Saint Louis, Missouri, to resolve lawsuits over the glyphosate-based herbicide made by Bayer after its 2018 acquisition of Monsanto. The payouts range from $10,000 to $165,000 for people who already have non-Hodgkin lymphoma. The deal also covers people exposed to Roundup who could develop the disease later, including those who never filed suit. Payments can be spread over 21 years. The judge validated the terms “in totality and definitively.” Bayer said the settlement text contains “no recognition of liability or guilt.” The company also pointed to a June decision by the US Supreme Court that favored Bayer. According to the Supreme Court ruling, the Environmental Protection Agency decision that Roundup is not cancerous takes precedence over lawsuits claiming a link between the product and cancer. The court said companies cannot be held responsible for failing to warn about cancer risk on Roundup. The Bayer group said glyphosate litigation has been costly, with more than 100,000 cases since 2018 and over $10 billion already paid. Glyphosate is described in the coverage as “probably carcinogenic” by the International Agency for Research on Cancer of the World Health Organization. The agreement was approved for cases managed through the court process, and it is now officially in force after the final approval.